Repligen Corporation (NASDAQ:RGEN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The firm presently has a $42.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 10.50% from the company’s current price.

According to Zacks, “Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUSĀ® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. “

Separately, First Analysis restated an “equal weight” rating and set a $40.00 price objective on shares of Repligen Corporation in a research note on Friday, April 21st.

Repligen Corporation (NASDAQ RGEN) opened at 38.01 on Wednesday. The firm’s 50-day moving average price is $38.29 and its 200 day moving average price is $33.80. Repligen Corporation has a 12-month low of $21.11 and a 12-month high of $40.48. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of 100.29 and a beta of 1.30.

Repligen Corporation (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, May 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.02. Repligen Corporation had a net margin of 11.93% and a return on equity of 9.57%. The company had revenue of $30.59 million during the quarter, compared to the consensus estimate of $29.28 million. During the same period in the prior year, the business posted $0.12 EPS. The company’s quarterly revenue was up 21.9% on a year-over-year basis. On average, equities research analysts expect that Repligen Corporation will post $0.56 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Repligen Corporation (RGEN) Rating Increased to Buy at Zacks Investment Research” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/14/repligen-corporation-rgen-rating-increased-to-buy-at-zacks-investment-research.html.

In other news, VP Howard Benjamin sold 12,216 shares of the stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $34.62, for a total transaction of $422,917.92. Following the completion of the transaction, the vice president now directly owns 36,124 shares in the company, valued at approximately $1,250,612.88. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Thomas F. Ryan, Jr. sold 4,000 shares of the stock in a transaction dated Monday, March 20th. The stock was sold at an average price of $34.83, for a total transaction of $139,320.00. Following the transaction, the director now owns 12,594 shares of the company’s stock, valued at $438,649.02. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,646 shares of company stock valued at $714,898. Company insiders own 1.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in Repligen Corporation by 143,196.5% in the first quarter. BlackRock Inc. now owns 4,664,302 shares of the biotechnology company’s stock worth $164,187,000 after buying an additional 4,661,047 shares in the last quarter. TimesSquare Capital Management LLC increased its position in Repligen Corporation by 35.1% in the first quarter. TimesSquare Capital Management LLC now owns 1,970,725 shares of the biotechnology company’s stock worth $69,370,000 after buying an additional 512,300 shares in the last quarter. Vanguard Group Inc. increased its position in Repligen Corporation by 7.0% in the first quarter. Vanguard Group Inc. now owns 1,809,202 shares of the biotechnology company’s stock worth $63,683,000 after buying an additional 118,585 shares in the last quarter. Conestoga Capital Advisors LLC boosted its stake in shares of Repligen Corporation by 8.6% in the first quarter. Conestoga Capital Advisors LLC now owns 1,215,810 shares of the biotechnology company’s stock worth $42,797,000 after buying an additional 95,942 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Repligen Corporation by 4.1% in the first quarter. State Street Corp now owns 1,102,145 shares of the biotechnology company’s stock worth $38,803,000 after buying an additional 42,949 shares during the last quarter. Institutional investors own 97.06% of the company’s stock.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Get a free copy of the Zacks research report on Repligen Corporation (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.